Intellia halts ATTR-CM gene editing trials after liver toxicity case
Intellia Therapeutics paused two phase 3 trials of its CRISPR-based therapy after a patient developed severe liver toxicity.
News
-
-
Structured exercise programs may help people with ATTR-CM
Structured exercise can improve strength and quality of life in people with ATTR-CM, according to a recent review.
-
ATTR-CM treatment options are growing, but more research is needed
New therapies have greatly expanded the options for treating ATTR-CM, but more research is needed on therapies that remove amyloid deposits.
-
Vutrisiran shows promise in alleviating gastrointestinal symptoms of ATTR-CM
A phase 3 study recently demonstrated that vutrisiran can lower the risk of gastrointestinal complications among patients with ATTR-CM.
-
Ageism may impact care of older patients with ATTR-CM
Age should not be the sole reason that potentially helpful disease-modifying therapies are withheld among older patients with ATTR-CM.
-
Lower skeletal mass and body fat increase mortality risk in ATTR-CM
Certain body mass assessments were associated with long-term patient outcomes in cardiac amyloidosis.
-
New study concludes all therapies specific to ATTR-CM yield better patient outcomes
The use of therapies specific to the disease processes in ATTR-CM is an excellent strategy to arrive at better outcomes.
-
New study explores how age at diagnosis impacts wild-type ATTR-CM
Age appears to have an impact in cardiac biomarker levels in patients with wild-type ATTR-CM while sex correlates with the age of diagnosis.
-
Lifestyle factors may impact risk of developing wild-type ATTR-CM
Lifestyle factors may contribute to the development of wild-type ATTR-CM via oxidative stress.
-
More research needed on long-term effects of TTR depletion in ATTR-CM treatment
A review highlights the many roles of transthyretin in the body and the potential implications of long-term suppression in patients with ATTR.
